Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (718,499)	$ (1,808,298)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	471,796	519,828
Bad debt expense	687,612	653,491
Share based compensation	109,690	159,058
Issuance of stock for compensation	70,000	336,000
Change in fair value of contingent consideration		(48,035)
Loss on disposal of property and equipment		3,228
Non-cash interest expense	51,240	53,117
Change in assets and liabilities
Accounts receivable	632,726	(3,206,920)
Other receivable		(837,708)
Inventories	286,847	558,342
Prepaid expenses and other current assets	(640,975)	(299,219)
Accounts payable and accrued liabilities	(224,452)	3,049,236
Deferred revenue	(22,227)	(16,785)
Net cash provided by (used in) operating activities	703,758	(884,665)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(52,438)	(127,128)
Cash paid for acquisition of PhotoMedex, Inc.		(5,000,000)
Net cash used in investing activities	(52,438)	(5,127,128)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of DermaWand asset purchase agreement	(150,000)	(150,000)
Proceeds from issuance of common stock, net of offering costs		6,982,930
Proceeds from exercise of options		55,559
Proceeds from note payable	145,000
Repayments of long-term debt to related party	(324,113)
Payments of deferred consideration for asset acquisition	(160,414)	(14,583)
Proceeds from issuance of preferred stock	403,200
Net cash (used in) provided by financing activities	(86,327)	6,873,906
Effect of exchange rates on cash and cash equivalents	(11,107)	2,031
NET INCREASE IN CASH AND CASH EQUIVALENTS	553,886	864,144
CASH AND CASH EQUIVALENTS, beginning of the period	1,258,360	1,390,641
CASH AND CASH EQUIVALENTS, end of the period	1,812,246	2,254,785
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Taxes paid
Interest paid	276,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITY:
Cashless exercise of options		23
Contingent consideration reclass to other receivable		570,248
PhotoMedex [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITY:
Fair value of assets acquired		9,198,043
Fair value of deferred consideration		(4,198,043)
Cash paid for acquisition		5,000,000
Ermis Labs [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITY:
Fair value of assets acquired		1,981,822
Fair value of deferred consideration		(1,131,822)
Issuance of common stock		(850,000)
Cash paid for acquisition